Emily Freeman MSc, PhDSenior Director, Global R&D Patient Insights
Lundbeck Pharmaceuticals LLC
Dr. Emily Freeman is a Senior Director of Global R&D Patient Insights at Lundbeck where she specializes in the understanding of patient insights and behaviors within drug development. Dr. Freeman is interested in the development of evidence-based communication tools to facilitate shared decision making for patients. Dr. Freeman is exploring how medical evidence (i.e. risk, benefit, and health outcomes) is constructed and communicated within the healthcare environment. Dr. Freeman is also interested in the development of digital health interventions and demonstrating their effectiveness. Finally, she has been involved for more than a decade in bringing a more patient-centered approach to drug development through patient-reported, centered, and defined outcomes.
In her previous roles at Bristol-Myers Squibb, Pfizer, Eli Lilly, AbbVie, and most recently Sanofi, Dr. Freeman conducted research to better incorporate the patient perspective into drug development through patient centered outcomes, effective risk minimization programs, and improving the regulatory science of patient preferences. In addition Dr. Freeman has been the principal investigator on various health outcomes studies within the pharmaceutical industry focused on improving the effectiveness of communication to HCP's/patients, understanding the experience of treatment on patient's quality of life/survival, improving medication adherence, and qualitative understanding of benefit-risk from the patient's perspective.
Dr. Freeman received her PhD degree in Health Geography/Medical Sociology from McMaster University with postdoctoral training in Palliative Care and Psychosocial Oncology from the University Of Toronto Faculty Of Psychiatry. Her substantive research interests include: patient engagement (social media, behavioral interventions, and health literacy), digital interventions and outcomes, clinical epidemiology, medication adherence, patient reported outcomes, risk communication, and shared treatment decision making.